

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|------------------------------|---|----|---|--------------------------|------------------------|
| Substitute for form 1449/PTO | | | | Complete If Known | |
| | | | | Application Number | 10/619,454-Conf. #7700 |
| | | | | Filing Date | July 16, 2003 |
| | | | | First Named Inventor | Cheryl Fitzer-Altas |
| | | | | Art Unit | 1649 |
| | | | | Examiner Name | S. H. Standley |
| Sheet | 1 | of | 4 | Attorney Docket Number | 20555/1203432-US1 |

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|-----------------------|---|--------------------------------|--|---|
| Examiner Initials* | Cite No. ¹ | Document Number Number-Kind Code ² (#known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| SS | AA* | US-4,582,788 | 04-15-1986 | Erlich | |
| SS | AB* | US-4,683,202-B1 | 07/1987 | Mullis | |
| SS | AC* | US-20040043935-A1 | 03-04-2004 | Frangione et al. | |
| SS | AD* | US-20030166558-A1 | 09-04-2003 | Frangione et al. | |

| FOREIGN PATENT DOCUMENTS | | | | | |
|--------------------------|-----------------------|--|--------------------------------|--|---|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (#known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| SS | BA | WO-99/27944 | 06-10-1999 | Athena Neurosciences Inc et al. | |
| SS | BB | WO-00/72876 | 12-07-2000 | Neuralab Ltd et al. | |
| SS | BC | WO-0190182 | 11-29-2001 | Univ New York et al. | |
| SS | BD | WO-03/045128 | 06-05-2003 | Univ New York et al. | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

| NON PATENT LITERATURE DOCUMENTS | | | | | |
|---------------------------------|-----------------------|---|--|--|--|
| Examiner Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | | | |
| SS | CA | Bauer, J. et al. "Inflammation in the nervous system: the human perspective". 2001 Glia 36: 235-243. | | | |
| SS | CB | Blen, C.G., et al. "Destruction of neurons by cytotoxic T cells: a new pathogenic mechanism in Rasmussen's encephalitis." Ann Neurol 2002 March; 51(3):311-8 | | | |
| SS | CC | Blasko I, et al., "B TNFalpha plus IFNgamma induce the production of Alzheimer beta-amyloid peptides and decrease the secretion of APPs." FASEB J 1999 January; 13(1):63-8 | | | |
| SS | CD | Busciglio, J. et al. "Generation of beta-amyloid in the secretory pathway in neuronal and normoneuronal cells." (1993) Proc Natl Acad Sci USA 90:2092-2096 | | | |
| SS | CE | Buus S, et al., "Receptor-ligand interactions measured by an improved spun column chromatography technique. A high efficiency and high throughput size separation method." Biochim Biophys Acta. Apr. 13, 1995; 1243(3):453-60. | | | |
| SS | CF | Check, E. "Nerve inflammation halts trial for Alzheimer's drug." Nature. Jan. 31, 2002;415(6871):462. | | | |
| SS | CG | Gay, F. W. et al. "The application of multifactorial cluster analysis in the staging of plaques in early multiple sclerosis: identification and characterization of the primary demyelinating lesion." | | | |

| | | | |
|-----------------------------------|-------------------|-----------------|--------------|
| Examiner Signature 0093852.doc | /Steven Standley/ | Date Considered | (2/15/06) |
| | | | 12/15/06 SS. |

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|------------------------------|---|----|---|--------------------------|------------------------|
| Substitute for form 1449/PTO | | | | <i>Complete if Known</i> | |
| | | | | Application Number | 10/619,454-Conf. #7700 |
| | | | | Filing Date | July 16, 2003 |
| | | | | First Named Inventor | Cheryl Fitzer-Attas |
| | | | | Art Unit | 1649 |
| | | | | Examiner Name | S. H. Standley |
| Sheet | 2 | of | 4 | Attorney Docket Number | 20555/1203432-US1 |

| | | | |
|----|----|---|--|
| | | Brain. 1997 August;120 (Pt 8):1461-83. | |
| SS | CH | Geddes, J. W. et al, "N-terminus truncated beta-amyloid peptides and C-terminus truncated secreted forms of amyloid precursor protein: distinct roles in the pathogenesis of Alzheimer's disease." <i>Neurobiol Aging</i> . 1999 20(1):75-9 | |
| SS | CI | Glenner, G. G. and Wong, C. W. "Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein." (1984) <i>Biochem Biophys Res Commun</i> 120:885-890. | |
| SS | CJ | Griffin D E, et al. "The immune response in viral encephalitis." <i>Semin Immunol</i> 1992 April; 4(2):111-9. | |
| SS | CK | Haass, C. et al. "Amyloid beta-peptide is produced by cultured cells during normal metabolism." (1992) <i>Nature</i> 359:322-325 | |
| SS | CL | Haas, C. et al, "Mutations associated with a locus for familial Alzheimer's disease result in alternative processing of amyloid b-protein precursor." <i>J Biol. Chem.</i> 269, 17741-17748. | |
| SS | CM | Higgins, L.S. et al, "p3 b amyloid peptide has a unique and potentially pathogenic immunohistochemical profile in Alzheimer's disease brain." <i>Am J. Pathol</i> 149, 585-598. | |
| SS | CN | Janus, C. et al. "A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease." 2000 <i>Nature</i> 408, 979-982. | |
| SS | CO | Joachim, C. L. et al. "Protein chemical and immunocytochemical studies of meningo-vascular beta-amyloid protein in Alzheimer's disease and normal aging." (1988) <i>Brain Res</i> 474:100-111 | |
| SS | CP | Kang, J. et al. "The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor." <i>Nature</i> . Feb. 19-25, 1987; 325(6108):733-6 | |
| SS | CQ | Kimura, T. & Griffin, D. E., "The role of CD8(+) T cells and major histocompatibility complex class I expression in the central nervous system of mice infected with neurovirulent Sindbis virus." <i>J Virol</i> 2000 July, 74(13):6117-25 | |
| SS | CR | Lalowski M et al., "The "nonamyloidogenic" p3 fragment (amyloid beta17-42) is a major constituent of Down's syndrome cerebellar preamyloid." 1996 <i>J Biol Chem</i> 271(52):33623-31 | |
| SS | CS | Lamer, A. J. "Hypothesis: amyloid b peptides truncated at the N-terminus contribute to the pathogenesis of Alzheimer's disease." <i>Neurobiol. Of Aging</i> 20, 65-69. | |
| SS | CT | Marx, F., "Transfected human B cells: a new model to study the functional and immunostimulatory consequences of APP production." <i>Exp Gerontol</i> 1999 September; 34(6):783-95 | |
| SS | CU | Morgan, D., et al. "A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease." 2000 <i>Nature</i> 408, 982-985. | |
| SS | CV | Mori, H. et al. "Mass spectrometry of purified amyloid beta protein in Alzheimer's disease." (1992) <i>J Biol Chem</i> 267:17082-17806. | |
| SS | CW | Naslund, J. et al. "Relative abundance of Alzheimer A beta amyloid peptide variants in Alzheimer disease and normal aging." (1994) <i>Proc Natl Acad Sci USA</i> 91:8378-8382. | |
| SS | CX | Neumann, H. et al. "Major histocompatibility complex (MIC) class I gene expression in single neurons of the central nervous system: differential regulation by Interferon (IFN)-gamma and tumor necrosis factor (TNF)-alpha." 1997 <i>J Exp Med</i> 185: 305-316. | |

| | | | |
|-----------------------|--------------------|--------------------|----------|
| Examiner Signature | <i>[Signature]</i> | Date Considered | 12/15/06 |
|-----------------------|--------------------|--------------------|----------|

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|------------------------------|---|----|---|------------------------|------------------------|
| Substitute for form 1449/PTO | | | | Complete if Known | |
| | | | | Application Number | 10/619,454-Conf. #7700 |
| | | | | Filing Date | July 16, 2003 |
| | | | | First Named Inventor | Cheryl Fitzer-Attas |
| | | | | Art Unit | 1649 |
| | | | | Examiner Name | S. H. Standley |
| Sheet | 3 | of | 4 | Attorney Docket Number | 20555/1203432-US1 |

| | | | |
|----|-----|--|--|
| SS | CY | Oldstone, M. B. & Southern, P. J., "Trafficking of activated cytotoxic T lymphocytes into the central nervous system: use of a transgenic model." 1993 J Neuroimmunol 46:25-31 | |
| SS | CZ | Ostergaard Pedersen L., et al, "Efficient assembly of recombinant major histocompatibility complex class I molecules with preformed disulfide bonds." Eur J. Immunol. 2001 October; 31(10):2986-96 | |
| SS | CA1 | Parker, K. C., et al, "Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains." J. Immunol. 152:163. | |
| SS | CB1 | Pike, C.J., et al, "Amino-terminal deletions enhance aggregation of β -amyloid peptides in vitro". J Biol Chem 270, 23895-8. | |
| SS | CC1 | Prelli, F. et al. "Differences between vascular and plaque core amyloid in Alzheimer's disease." (1988) J Neurochem 51:648-651 | |
| SS | CD1 | Rammensee, Hans-Georg, et al. "SYFPEITHI: database for MHC ligands and peptide motifs." Immunogenetics (1999) 50: 213-219 (access via: http://www.uni-tuebingen.de/unil/kxi/) | |
| SS | CE1 | Reche, P.A., et al. "Prediction of MHC Class I Binding Peptides Using Profile Motifs." Human Immunology 63, 701-709 (2002). | |
| SS | CF1 | Roher, A. E. et al. "beta-Amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease." (1993) Proc Natl Acad Sci USA 90:10836-10840 | |
| SS | CG1 | Schenk, D. et al. "Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse." 1999 Nature 400, 173-177. | |
| SS | CH1 | Seubert, P. et al. "Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids." (1992) Nature 359:325-327 | |
| SS | CI1 | Stuiniolo, T., et al., "Generation of tissue-specific and promiscuous HLA ligand database using DNA microarrays and virtual HLA class II matrices." Nat. Biotechnol. 17. 555-561(1999) | |
| SS | CJ1 | Tekirian, T.L., "Commentary: Abeta N-Terminal Isoforms: Critical contributors in the course of AD pathophysiology." J Alzheimers Dis. 2001 April; 3(2):241-248. | |
| SS | CK1 | Traugott, U. "Multiple sclerosis: relevance of class I and class II MHC-expressing cells to lesion development." 1987 J Neuropathol 16: 283-302. | |
| SS | CL1 | Vass, K. & Lassmann, H. "Intrathecal application of interferon gamma. Progressive appearance of MHC antigens within the rat nervous system." 1990 Am J. Pathol 137: 789-800. | |
| SS | CM1 | Scharf et al., "Direct Cloning and Sequence Analysis of Enzymatically Amplified Genomic Sequences." Science, Vol. 233, No. 4768, pp. 1076-1078 | |
| SS | CN1 | Cox et al., "HLA-DR Typing "at the DNA Level": RFLPs and Subtypes Detected with a DR β cDNA Probe." Am. J. Hum. Gen., 43:954-963, 1988 | |
| SS | CO1 | Tiercy, Jean-Marie, et al., "Identification and Distribution of Three Serologically Undetected Alleles of HLA-DR by Oligonucleotide-DNA Typing Analysis." Proc. Natl. Acad. Sci. USA, Vol. 85, pp. 198-202, 1988 | |
| SS | CP1 | Tiercy, Jean-Marie, et al., "DNA Typing of DRw6 Subtypes: Correlation with DRB1 and DRB3 Allelic Sequences by Hybridization with Oligonucleotide Probes." Hum. Immunol. 24, pp. 1-14 (1989) | |
| SS | CQ1 | Salki, Randall K., et al., "Analysis of Enzymatically Amplified β -globin and HLA-DQ α DNA with | |

| | | | |
|------------------------------------|-------------------|-----------------|----------|
| Examiner Signature 00939832.doc | /Steven Standley/ | Date Considered | 12/15/06 |
|------------------------------------|-------------------|-----------------|----------|

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|------------------------------|---|----|---|--------------------------|------------------------|
| Substitute for form 1449/PTO | | | | Complete If Known | |
| | | | | Application Number | 10/619,454-Conf. #7700 |
| | | | | Filing Date | July 16, 2003 |
| | | | | First Named Inventor | Cheryl Fitzer-Attas |
| | | | | Art Unit | 1649 |
| | | | | Examiner Name | S. H. Standley |
| Sheet | 4 | of | 4 | Attorney Docket Number | 20555/1203432-US1 |

| | | | |
|----|-----|--|--|
| | | Allele-Specific Oligonucleotide Probes." Nature, Vol. 324, pp. 163-166, 1986 | |
| SS | CR1 | Bugawan, Theodorica L., et al., "Analysis of HLA-DP Allelic Sequence Polymorphism Using the In Vitro Enzymatic NDA Amplification of DP- α and DP- β Loci." J. Immunol., Vol. 141, No. 12, pp. 4024-4030, 1988 | |
| SS | CS1 | Gyllensten, Ulf B., et al., "Generation of Single-Stranded DNA by the Polymerase Chain Reaction and its Application to Direct Sequencing of the HLA-DQA Locus." Proc. Natl. Acad. Sci. USA, Vol. 85, pp. 7652-7656, 1988 | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

| | | | |
|---------------------------------------|-------------------|--------------------|----------|
| Examiner Signature 00939052.doc | /Steven Standley/ | Date Considered | 12/18/06 |
|---------------------------------------|-------------------|--------------------|----------|